GID 0.00% 0.2¢ gi dynamics, inc

Ann: New Clinical Data on EndoBarrier Therapy Presented at EASD, page-2

  1. 709 Posts.
    lightbulb Created with Sketch. 277
    Evening all
    This is really good data. Very happy with this. May not change SP quickly but will help a lot with Gov negotiations re payment. Clearly works with far less side effects than banding, is reversible and quickly implantable in people who can not have surgery due to the extreme obesity and metabolic conditions being treated in the first place. SP has been quiet but will sig improve over next year or so as the pivotal trials finish.
    If I were to contemplate gastric surgery the endobarrier would be top of the list now due to the physiological changes, ease of use and diabetes improvement.

    Cheers all
 
watchlist Created with Sketch. Add GID (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.